EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Towards the Targeted Protein Degradation of PRMT1

Poppy L Martin, Francisco Javier Pérez-Areales, Shalini V Rao, Stephen J Walsh, Jason S Carroll, David R Spring iD

ChemMedChem · 2024

DOI: 10.1002/cmdc.202400269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Poppy L Martin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, United Kingdom. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Proteolysis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Medical Research Council, Fundación Ramón Areces, Marie Skłodowska-Curie Individual Fellowships.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting the protein arginine methyltransferase 1 (PRMT1) has emerged as a promising therapeutic strategy in cancer treatment. The phase 1 clinical trial for GSK3368715 , the first PRMT1 inhibitor to enter the clinic, was terminated early due to a lack of clinical efficacy, extensive treatment‐emergent effects, and dose‐limiting toxicities. The incidence of the latter two events may be associated with inhibition‐driven pharmacology as a high and sustained concentration of inhibitor is required for therapeutic effect. The degradation of PRMT1 using a proteolysis targeting chimera (PROTAC) may be superior to inhibition as proceeds via event‐driven pharmacology where a PROTAC acts catalytically at a low dose. PROTACs containing the same pharmacophore as GSK3368715 , combined with a motif that recruits the VHL or CRBN E3‐ligase, were synthesised. Suitable cell permeability and target engagement were shown for selected candidates by the detection of downstream effects of PRMT1 inhibition and by a NanoBRET assay for E3‐ligase binding, however the candidates did not induce PRMT1 degradation. This paper is the first reported investigation of PRMT1 for targeted protein degradation and provides hypotheses and insights to assist the design of PROTACs for PRMT1 and other novel target proteins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesProteolysisHumansRepressor ProteinsEnzyme InhibitorsUbiquitin-Protein LigasesMolecular StructureDose-Response Relationship, DrugStructure-Activity RelationshipAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

Heterobifunctional MoleculePRMT1PROTACProtein Arginine MethyltransferaseTargeted Protein Degradation

Substanzen

Protein-Arginine N-MethyltransferasesPRMT1 protein, humanCRBN protein, humanRepressor ProteinsEnzyme InhibitorsUbiquitin-Protein LigasesAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, United Kingdom.
  • Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, CH2 ORE, United Kingdom.

ORCID-Profile: David R Spring

Förderung

  • UK Medical Research Council
  • Fundación Ramón Areces
  • Marie Skłodowska-Curie Individual Fellowships
  • Cancer Research UK Core funds
  • Pancreatic Research Fund
  • Pancreatic Cancer UK
  • Medical Research Council

Zitieren

APA

Martin, P. L., Pérez-Areales, F. J., Rao, S. V., Walsh, S. J., Carroll, J. S., & Spring, D. R. (2024). Towards the Targeted Protein Degradation of PRMT1. ChemMedChem. https://doi.org/10.1002/cmdc.202400269

Vancouver

Martin PL, Pérez-Areales FJ, Rao SV, Walsh SJ, Carroll JS, Spring DR. Towards the Targeted Protein Degradation of PRMT1. ChemMedChem. 2024. doi:10.1002/cmdc.202400269

BibTeX
@article{Martin2024,
  author = {Martin, Poppy L and Pérez-Areales, Francisco Javier and Rao, Shalini V and Walsh, Stephen J and Carroll, Jason S and Spring, David R},
  title = {Towards the Targeted Protein Degradation of PRMT1},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202400269}
}
Kostenlos starten →